Lymphoma
This schema is for a majority of the lymphomas. Lymphomas not included in this schema include Mycosis Fungoides, Primary Cutaneous Lymphomas, Lymphoma Ocular Adnexa, and Lymphoma-CLL/SLL.
Lymphoma staging applies only to the stage group and is based on whether the lymphoma is nodal or extranodal, as well as the overall extent of disease throughout the body.
| Data Item | Criteria/Comments |
|---|---|
| Histologies | Majority of lymphomas (excluding the schemas and primary sites listed above) |
| Primary Sites | Most of the primary sites (excluding the schemas and primary sites listed above) |
| EOD Primary Tumor | Single nodal or single extranodal organ involved |
| Two or more nodal regions involved | |
| Single extranodal organ involved with regional lymph nodes | |
| Any of the above with bulky disease | |
| Lymph nodes involved on both sides of the diaphragm with or without spleen involvement, or lymph nodes involved above the diaphragm with spleen involvement | |
| Diffuse, disseminated or multifocal involvement | |
| Peripheral blood involvement only | |
| Metastasis: bone, CNS, bone marrow, CSF, liver, lung | |
| EOD Regional Nodes | Not applicable (Code to 888) |
| EOD Mets | Not applicable (Code to 88) |
| Summary Stage | Code 1: Single nodal or extranodal lymphoma |
| Code 2: Multiple nodal regions involved, extranodal lymphoma with regional lymph node involvement, bulky disease | |
| Code 7: Lymph nodes above and below the diaphragm, diffuse or disseminated involvement, involvement of the bone marrow/peripheral blood, spleen, CSF, liver, lung | |
| B symptoms (SSDI)* | These are systemic symptoms of fever, night seats, and weight loss. They are associated with both Hodgkin and non-Hodgkin lymphomas. More common in late stage lymphomas |
| HIV status (SSDI)* | HIV positive patients are at a higher risk of developing lymphomas |
| NCCN IPI (SSDI)* | This is the NCCN International Prognostic Index (IPI). It is for non-Hodgkin lymphomas only. Mostly used with diffuse large B-cell lymphoma (9680/3) |
| PTLD (SSDI)* | This new SSDI introduced in 2025 captures the presence of PTLD when there is a diagnosis of lymphoma, plasmacytoma, and myeloma. See Rules M14 and PH1 in the Hematopoietic manual for more information. |
*See the SSDI manual or SEER*RSA for more information on this data item.
Updated: December 2, 2025